Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Aug 1;84(2):236-44.
doi: 10.1002/ccd.25384. Epub 2014 Feb 5.

Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca⁺⁺ trial

David Roberts  1 , Khusrow Niazi, William Miller, Prakash Krishnan, Roger Gammon, Theodore Schreiber, Nicolas W Shammas, Daniel Clair; DEFINITIVE Ca⁺⁺ Investigators
Affiliations
Free PMC article
Clinical Trial

Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca⁺⁺ trial

David Roberts et al. Catheter Cardiovasc Interv. .
Free PMC article

Abstract

Objectives: The purpose of the DEFINITIVE Ca(++) study was to evaluate the safety and effectiveness of directional atherectomy and distal embolic protection, used together to treat moderate to severely calcified femoropopliteal lesions.

Background: Despite advances in endovascular treatment modalities, treatment of calcified lesions remains a challenge.

Methods: A total of 133 subjects with 168 moderate to severely calcified lesions were enrolled. Lesions were treated with directional atherectomy devices, coupled with distal embolic protection.

Results: The 30-day freedom from MAE rate was 93.1%. Per angiographic core laboratory assessment, the primary effectiveness endpoint (≤50% residual diameter stenosis) was achieved in 92.0% (lower confidence bound of 87.6%) of lesions. By core lab analysis, these results did not achieve the success criteria (90%) for the primary effectiveness objective. Per site assessment, the objective was met with the endpoint being achieved in 97.0% (lower confidence bound 93.8%). A mean residual diameter stenosis of 33.3% was achieved with the directional atherectomy device. This was further decreased to 24.1% with the use of adjunctive therapy. The proportion of asymptomatic subjects [Rutherford Clinical Category (RCC) = 0] increased from 0% at baseline to 52.3% at the 30-day follow-up visit. In total, 88.5% of subjects experienced an improvement of one or more Rutherford categories.

Conclusions: The results of the DEFINITIVE Ca++ study demonstrate that the SilverHawk and TurboHawk atherectomy devices are safe and effective in the endovascular treatment of moderate to severely calcified lesions in the superficial femoral and/or popliteal arteries when used with the SpiderFX distal embolic protection device.

Keywords: atherosclerosis; filter protection; peripheral arterial disease; peripheral vascular disease; plaque excision; revascularization.

PubMed Disclaimer

Figures

Fig 1
Fig 1
TurboHawk plaque excision system. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Fig 2
Fig 2
SpiderFX embolic protection device. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
See this image and copyright information in PMC

Comment in

References

    1. Kandzari DE, Kiesz RS, Allie D, Walker C, Fail P, Ramaiah VG, et al. Procedural and clinical outcomes with catheter-based plaque excision in critical limb ischemia. J Endovasc Ther. 2006;13:12–22. - PubMed
    1. Keeling WB, Shames ML, Stone PA, Armstrong PA, Johnson BL, Back MR, et al. Plaque excision with the Silverhawk catheter: early results in patients with claudication or critical limb ischemia. J Vasc Surg. 2007;45:25–31. - PubMed
    1. McKinsey JF, Goldstein L, Khan HU, Graham A, Rezeyat C, Morrissey NJ, et al. Novel treatment of patients with lower extremity ischemia: Use of percutaneous atherectomy in 579 lesions. Ann Surg. 2008;248:519–528. - PubMed
    1. Ramaiah V, Gammon R, Kiesz S, Cardenas J, Runyon JP, Fail P, et al. Midterm outcomes from the TALON Registry: Treating peripherals with SilverHawk: Outcomes collection. J Endovasc Ther. 2006;13:592–602. - PubMed
    1. Yancey AE, Minion DJ, Rodriguez C, Patterson DE, Endean ED. Peripheral atherectomy in TransAtlantic InterSociety Consensus type C femoropopliteal lesions for limb salvage. J Vasc Surg. 2006;44:503–509. - PubMed

MeSH terms